Market Place
Sourcing Support
Combined Shareholders’ General Meeting Votes Results Dec 11, 2024
12 Dec 2024 //
GLOBENEWSWIRE
Inventiva reports 2024 Third Quarter Financial Information¹
21 Nov 2024 //
GLOBENEWSWIRE
Combined General Meeting Prep Documents Available For Dec 11, 2024
20 Nov 2024 //
GLOBENEWSWIRE
Company Share Capital And Voting Rights As Of Nov 4, 2024
20 Nov 2024 //
GLOBENEWSWIRE
Inventiva to Present Ph 2 Lanifibranor & Empagliflozin Data at AASLD
15 Nov 2024 //
GLOBENEWSWIRE
Inventiva Receives Positive NATiV3 Phase 3 DMC Recommendation
30 Oct 2024 //
GLOBENEWSWIRE
Inventiva Secures Up To Advance €348M For Ph 3 MASH Study
14 Oct 2024 //
GLOBENEWSWIRE
Inventiva Announces Filing Of 2024 Half-Year Report
14 Oct 2024 //
GLOBENEWSWIRE
Inventiva Announces Availability Of Prospectus For Financing
14 Oct 2024 //
GLOBENEWSWIRE
Inventiva Reports Preliminary 2024 First-Half Financial Information¹
31 Jul 2024 //
GLOBENEWSWIRE
Inventiva Gets New Patent In Japan For Lanifibranor
25 Jul 2024 //
GLOBENEWSWIRE
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
19 Jul 2024 //
GLOBENEWSWIRE
Inventiva announces a €20.1 million issuance of royalty certificates
18 Jul 2024 //
GLOBENEWSWIRE
Inventiva Updates On NATiV3 Program For Lanifibranor In MASH/NASH And Finances
05 Jul 2024 //
GLOBENEWSWIRE
Share Repurchase Program Authorized Ordinary General Meeting
21 Jun 2024 //
GLOBENEWSWIRE
Statement Of Voting Rights And Shares At EssilorLuxottica
30 May 2024 //
GLOBENEWSWIRE
Ipsen Combined Meeting June 20 - Preparatory Docs Available
30 May 2024 //
GLOBENEWSWIRE
Inventiva Presentations At EASL 2024 On Liver Disease
22 May 2024 //
GLOBENEWSWIRE
Inventiva Reports Q1 2024 Financials, Provides Corporate Update
21 May 2024 //
GLOBENEWSWIRE
Inventiva Announces Positive Lanifibranor DMC Recommendation In NATiV3
16 May 2024 //
GLOBENEWSWIRE
Inventiva Publishes NATIVE Phase 2b Cardiometabolic Marker Results
13 May 2024 //
GLOBENEWSWIRE
Inventiva stock sinks 20% after serious adverse event in NASH trial
16 Feb 2024 //
ENDPTS
Inventiva reports preliminary 2023 fiscal year financial Information
15 Feb 2024 //
GLOBENEWSWIRE
Half-Year Review of Inventivas Liquidity Contract with Kepler Cheuvreux
24 Jan 2024 //
GLOBENEWSWIRE
Inventiva draws down the second tranche of €25M under existing Finance Contract
10 Jan 2024 //
GLOBENEWSWIRE
Inventiva announces the randomization of the first patient in the NATiV3 trial
20 Dec 2023 //
GLOBENEWSWIRE
Inventiva announces recommendation of third DMC of the Phase III clinical trial
04 Dec 2023 //
GLOBENEWSWIRE
Inventiva reports 2023 Third Quarter Financial Information¹
21 Nov 2023 //
GLOBENEWSWIRE
Inventiva announces a late breaker abstract on its lead compound, lanifibranor
06 Nov 2023 //
GLOBENEWSWIRE
Inventiva reports its 2023 first-half financial results
28 Sep 2023 //
GLOBENEWSWIRE
Inventiva, Kezar sell Asian rights to NASH and autoimmune assets
21 Sep 2023 //
FIERCE BIOTECH
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement
20 Sep 2023 //
GLOBENEWSWIRE
Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information
27 Jul 2023 //
GLOBENEWSWIRE
Inventiva reports positive topline data from T2D and NAFLD therapy trial
14 Jun 2023 //
CLINICAL TRIALS ARENA
Inventiva announces positive results from Phase II trial evaluating lanifibranor
13 Jun 2023 //
GLOBENEWSWIRE
Inventiva and Echosens launch joint initiative to increase NASH awareness
08 Jun 2023 //
GLOBENEWSWIRE
Inventiva announces five scientific presentations at the EASL
07 Jun 2023 //
GLOBENEWSWIRE
Results of votes of the Combined Shareholders General Meeting of May 25, 2023
26 May 2023 //
GLOBENEWSWIRE
Description of Share Repurchase Program Authorised by General Meeting
25 May 2023 //
GLOBENEWSWIRE
Sino received IND approval from the NMPA to initiate trial with lanifibranor
25 May 2023 //
GLOBENEWSWIRE
Inventiva reports 2023 First Quarter Financial Information and provides update
16 May 2023 //
GLOBENEWSWIRE
Inventiva announces filing of its 2022 Universal Registration Document
30 Mar 2023 //
GLOBENEWSWIRE
Inventiva reports its 2022 full-year results
29 Mar 2023 //
GLOBENEWSWIRE
Inventiva announces the schedule of publication & presentation of its 2022 FYR
23 Mar 2023 //
GLOBENEWSWIRE
Inventiva reports preliminary financial results for Full-Year 2022¹
14 Feb 2023 //
GLOBENEWSWIRE
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
30 Jan 2023 //
GLOBENEWSWIRE
Inventiva announces changes to the clinical development of lanifibranor
04 Jan 2023 //
GLOBENEWSWIRE
Inventiva secures a new patent expanding the IP protection of lanifibranor
28 Nov 2022 //
GLOBENEWSWIRE
Inventiva announces a new Director of the Board of Directors
21 Nov 2022 //
GLOBENEWSWIRE
AbbVie sheds autoimmune disease drug in blow to partner Inventiva
31 Oct 2022 //
PHARMAPHORUM
Inventiva announces a scientific presentation at the AASLD The Liver Meeting
21 Oct 2022 //
GLOBENEWSWIRE
Inventiva and Sino Biopharm ink NASH deal for more than $300 M
27 Sep 2022 //
BIOSPECTRUMASIA
Inventiva reports its 2022 first-half financial results and provides
22 Sep 2022 //
GLOBENEWSWIRE
Inventiva signs over China NASH rights to Sino Biopharm in possible $300M+ deal
22 Sep 2022 //
ENDPTS
Inventiva & Sino Biopharm announce licensing collaboration agreemen lanifibranor
21 Sep 2022 //
GLOBENEWSWIRE
Inventiva Reports 2022 First-Half Financial Information
28 Jul 2022 //
GLOBENEWSWIRE
Inventiva announces screening of first patient in LEGEND, PIIa combination trial
07 Jul 2022 //
GLOBENEWSWIRE
Update on Inventiva`s cash position and on the finance documentation with EIB
04 Jul 2022 //
GLOBENEWSWIRE
Inventiva to host a webcast with Key Opinion Leaders following the EASL 2022
16 Jun 2022 //
GLOBENEWSWIRE
